$62.54
-0.41-0.65%
At close: -
$62.85
0.310.50%
After Hours: 4:00 PM EDT
Comments
Loading...
Halozyme Therapeutics Stock Guidance | NASDAQ:HALO | Benzinga
Halozyme Therapeutics issues guidance on future EPS and revenue, giving investors insight into how much the company expects to earn in upcoming periods.
| Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 02/18/2025 | HALO | Halozyme Therapeutics | FY | 2025 | $4.95 | $5.35 | $5.05 | $1.15B | $1.23B | $1.18B | Get Alert |
| 01/08/2025 | HALO | Halozyme Therapeutics | FY | 2024 | $4.00 | $4.20 | $4.14 | $970.00M | $1.02B | $1.00B | Get Alert |
| 01/08/2025 | HALO | Halozyme Therapeutics | FY | 2025 | $4.95 | $5.35 | $4.69 | $1.15B | $1.23B | $1.16B | Get Alert |
| 10/31/2024 | HALO | Halozyme Therapeutics | FY | 2024 | $4.00 | $4.20 | $3.96 | $970.00M | $1.02B | $983.85M | Get Alert |
| 08/06/2024 | HALO | Halozyme Therapeutics | FY | 2024 | $3.65 | $4.05 | $3.99 | $935.00M | $1.01B | $989.87M | Get Alert |
| 06/06/2024 | HALO | Halozyme Therapeutics | FY | 2024 | $3.65 | $4.05 | $3.73 | $935.00M | $1.01B | $947.33M | Get Alert |
| 05/07/2024 | HALO | Halozyme Therapeutics | FY | 2024 | $3.55 | $3.90 | $3.68 | $915.00M | $985.00M | $951.47M | Get Alert |
| 02/20/2024 | HALO | Halozyme Therapeutics | FY | 2024 | $3.55 | $3.90 | $3.51 | $915.00M | $985.00M | $961.09M | Get Alert |
| 01/17/2024 | HALO | Halozyme Therapeutics | FY | 2023 | $2.77 | $2.80 | $2.74 | $827.00M | $832.00M | $835.69M | Get Alert |
| 11/06/2023 | HALO | Halozyme Therapeutics | FY | 2023 | $2.70 | $2.80 | $2.65 | $825.00M | $845.00M | $835.91M | Get Alert |
| 08/08/2023 | HALO | Halozyme Therapeutics | FY | 2023 | $2.65 | $2.75 | $2.61 | $825.00M | $845.00M | $823.06M | Get Alert |
| 05/09/2023 | HALO | Halozyme Therapeutics | FY | 2023 | $2.50 | $2.65 | $2.57 | $815.00M | $845.00M | $833.00M | Get Alert |
| 03/15/2023 | HALO | Halozyme Therapeutics | FY | 2023 | — | — | — | $815.00M | $845.00M | $829.01M | Get Alert |
| 02/21/2023 | HALO | Halozyme Therapeutics | FY | 2023 | $2.50 | $2.65 | $2.78 | $815.00M | $845.00M | $868.12M | Get Alert |
| 01/10/2023 | HALO | Halozyme Therapeutics | FY | 2023 | $2.50 | $2.65 | $2.90 | $815.00M | $845.00M | $892.47M | Get Alert |
| 11/08/2022 | HALO | Halozyme Therapeutics | FY | 2022 | $2.10 | $2.25 | $2.04 | $655.00M | $685.00M | $661.33M | Get Alert |
| 08/09/2022 | HALO | Halozyme Therapeutics | FY | 2022 | $2.10 | $2.25 | $2.23 | $655.00M | $685.00M | $610.87M | Get Alert |
| 05/10/2022 | HALO | Halozyme Therapeutics | FY | 2022 | $2.05 | $2.20 | $2.23 | $530.00M | $560.00M | $566.18M | Get Alert |
| 04/13/2022 | HALO | Halozyme Therapeutics | FY | 2022 | $2.05 | $2.20 | $2.18 | $530.00M | $560.00M | $553.27M | Get Alert |
| 02/22/2022 | HALO | Halozyme Therapeutics | FY | 2022 | $2.05 | $2.20 | $2.18 | $530.00M | $560.00M | $554.20M | Get Alert |
| 01/10/2022 | HALO | Halozyme Therapeutics | FY | 2022 | $2.05 | $2.20 | $2.68 | $530.00M | $560.00M | $569.39M | Get Alert |
| 11/02/2021 | HALO | Halozyme Therapeutics | FY | 2021 | $1.90 | $2.00 | — | $430.00M | $445.00M | — | Get Alert |
| 08/09/2021 | HALO | Halozyme Therapeutics | FY | 2021 | $1.85 | $2.00 | $1.41 | $425.00M | $445.00M | $404.56M | Get Alert |
| 05/10/2021 | HALO | Halozyme Therapeutics | FY | 2021 | $1.55 | $1.70 | $1.55 | $375.00M | $395.00M | $389.96M | Get Alert |
| 02/23/2021 | HALO | Halozyme Therapeutics | FY | 2021 | $1.40 | $1.55 | $1.70 | $375.00M | $395.00M | $400.15M | Get Alert |
| 01/13/2021 | HALO | Halozyme Therapeutics | FY | 2020 | $0.90 | $0.95 | $0.93 | $265.00M | $275.00M | $265.30M | Get Alert |
| 01/11/2021 | HALO | Halozyme Therapeutics | FY | 2021 | $1.40 | $1.55 | $1.79 | $375.00M | $395.00M | $403.71M | Get Alert |
| 11/23/2020 | HALO | Halozyme Therapeutics | FY | 2020 | $0.90 | $0.95 | $0.86 | $265.00M | $275.00M | $255.12M | Get Alert |
| 11/02/2020 | HALO | Halozyme Therapeutics | FY | 2020 | $0.80 | $0.85 | $0.69 | $250.00M | $260.00M | $235.94M | Get Alert |
FAQ
What is the most recent guidance for Halozyme Therapeutics (HALO)?
The most recent guidance for Halozyme Therapeutics (HALO) was reported on February 18, 2025 for the full year 2025. The company provided earnings per share guidance in the range of $4.95 to $5.35, compared to the estimated EPS of $5.05. Additionally, Halozyme Therapeutics forecasted revenue between $1.15B and $1.23B for the quarter.
Browse guidance and forecast on all stocks.